Dr. David Reddy has been CEO of Medicines for Malaria Venture since January 2011. Under his leadership, this not for profit research foundation has seen 2 new antimalarial drugs approved (Eurartesim and Pyramax), progressed 7 novel compounds into clinical development, implemented a new 5-year business plan. MMV’s renewed business objectives include developing more convenient regimens that achieve radical cure of both P. falciparum and P. vivax, including ACT-resistant strains, and can be used safely in children and pregnant women.
Prior to joining MMV, David was a Vice President in the Global Product Strategy unit at F. Hoffman-La Roche Ltd, Basel Switzerland. His résumé includes over 20 years of ‘Pharma’ experience, including successful leadership of drug development teams, licensing and alliance management, market analytics and business planning, product and disease area management, and interfacing with governments, NGOs and patient advocacy groups around access to medicines for priority diseases including HIV/AIDS and pandemic influenza.
David holds an MSc (Hons) in Cell Biology and a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand.
Abstracts this author is presenting: